Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
It has been postulated that delta sleep-inducing peptide (DSIP) possesses an agonistic activity on opiate receptors and might be of value in the treatment of withdrawal syndromes. To test this hypothesis, DSIP (25 nmol/kg) was injected intravenously as sole treatment to 67 patients presenting withdrawal symptoms (28 from ethyl alcohol, 39 from opiates). 27% of the patients were lost or unsuitable for evaluation. From the 49 evaluable patients, DSIP produced a beneficial effect in 48 (22 alcoholics and 26 from 27 opiate addicts), with an immediate onset of action, a good and lasting suspension of the somatic symptoms and signs. Anxiety resolved more slowly, within hours. No major side-effect occurred. DSIP offers a new physiologically-based approach for the treatment of established withdrawal syndrome.
D000328:Adult; D003701:Delta Sleep-Inducing Peptide; D004341:Drug Evaluation; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009294:Narcotics / Q000009:adverse effects*; D009419:Nerve Tissue Proteins / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use*; D011957:Receptors, Opioid / Q000187:drug effects*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
D009294:Narcotics; D009419:Nerve Tissue Proteins; D009842:Oligopeptides; D011957:Receptors, Opioid; D000431:Ethanol; D003701:Delta Sleep-Inducing Peptide